一品红(300723) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 515.71 million, a slight increase of 0.18% compared to CNY 514.76 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 79.79 million, representing a year-on-year growth of 17.27% from CNY 68.04 million[4]. - The net profit after deducting non-recurring gains and losses was CNY 71.16 million, up 10.20% from CNY 64.58 million in the previous year[4]. - The net cash flow from operating activities increased significantly by 144.77% to CNY 28.07 million, compared to CNY 11.47 million in the same period last year[4]. - Total comprehensive income attributable to the parent company's owners increased to 79,793,126.38 from 68,040,684.42, representing a growth of approximately 17.5%[41]. - Basic and diluted earnings per share rose to 0.28 from 0.24, reflecting a 16.7% increase[41]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3.98 billion, a 7.45% increase from CNY 3.70 billion at the end of the previous year[4]. - Total assets increased to ¥3,980,505,214.39 from ¥3,704,414,827.97, representing a growth of approximately 7.43% year-over-year[31]. - Total liabilities rose to ¥1,902,770,717.15, up from ¥1,686,031,905.65, indicating an increase of about 12.85%[31]. - The total liabilities to total assets ratio is approximately 47.8%, indicating a stable leverage position[31]. Revenue and Costs - Operating revenue for the current period was ¥515,706,771.99, slightly up from ¥514,757,244.68, showing a marginal growth of 0.18%[35]. - Total operating costs decreased to ¥438,187,253.22 from ¥445,249,979.39, reflecting a reduction of approximately 1.47%[35]. Research and Development - Research and development expenses increased by 26.54%, driven by accelerated investment in ongoing projects[9]. - Research and development expenses increased to ¥34,242,800.51 from ¥27,060,888.66, representing a growth of approximately 26.93%[35]. - The company is focusing on enhancing its R&D capabilities through various innovative mechanisms to mitigate risks associated with drug development[24]. Shareholder Information - Guangdong Guangrun Group Limited holds 42.49% of the shares, totaling 122,400,000 shares[13]. - Wu Meirong, a natural person, holds 5.90% of the shares, totaling 16,991,040 shares, with 13,592,832 shares pledged[13]. - Li Hanxiong, a natural person, holds 5.75% of the shares, totaling 16,560,000 shares, with 13,248,000 shares pledged[13]. - Guangzhou Fuze Investment Management Center (Limited Partnership) holds 5.62% of the shares, totaling 16,200,000 shares[13]. - The total number of ordinary shareholders at the end of the reporting period is 10,915[13]. Cash Flow - Cash inflow from operating activities totaled 604,375,791.80, up from 569,479,774.31, indicating a growth of about 6.5%[42]. - Cash outflow from investment activities was 867,375,742.98, compared to 714,348,600.84, showing an increase of around 21.5%[45]. - Net cash flow from financing activities decreased to 334,117,705.69 from 469,706,220.31, a decline of about 29%[48]. - The ending cash and cash equivalents balance was 897,727,783.16, slightly down from 898,619,042.35, indicating a decrease of approximately 0.1%[48]. Investments and Subsidiaries - The company completed a capital increase of ¥49,880,660 for its subsidiary, raising its stake in Huannan Vaccine from 52.7077% to 58.9582%[24]. - The company completed an investment of CNY 15 million in a biopharmaceutical investment partnership, marking a significant operational phase[8]. Government Support - The company received government subsidies amounting to CNY 4.18 million, contributing to a significant increase in non-operating income by 5,760.09%[12].